Compass Pathways Plc ADR (CMPS) Stock Price, Quote & News

Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company...

Industry: Medical Care Facilities

Sector: Healthcare

Phone: 44 716 6766461

Website: compasspathways.com

Address:

33 Broadwick Street, London, United Kingdom

Indialli1309 Jun. 9 at 8:29 AM

$CMPS There is something good cooking! Last time CMPS was on the top 10 in TRENDING it went 40% up!

1 · Reply

Indialli1309 Jun. 9 at 8:09 AM

$CMPS Let’s stop sucking our thumb! CMPS is a fantastic company with a fantastic product. Two options, buy or hold. This is happening😇

0 · Reply

Indialli1309 Jun. 9 at 8:07 AM

$CMPS https://vicentellp.com/insights/comp360-rems-and-what-fda-psychedelic-approval-path-means-for-investors-and-operators/

0 · Reply

Indialli1309 Jun. 9 at 8:04 AM

$CMPS https://www.medicaldaily.com/chicagos-va-hospital-just-enrolled-its-first-veterans-psilocybin-assisted-therapy-program-475537

0 · Reply

Sibtsen Jun. 9 at 5:45 AM

$CMPS For those who are new here, I highly recommend watching How to Change Your Mind, Fantastic Fungi, or In Waves and War on Netflix. Psychedelic-assisted therapies have the potential to be life-changing for people struggling with depression, PTSD, and other mental health conditions. Many members of this community have shared personal stories about the profound positive impact these treatments have had on their lives. If approved and widely adopted, they could offer a powerful alternative to traditional antidepressants for many patients, with the potential for rapid and long-lasting benefits after only one or a few treatment sessions. #trending

0 · Reply

Hobson73 Jun. 9 at 5:05 AM

$CMPS anyone here have an average in the $2 range? Show receipts so I can be jealous

0 · Reply

Hobson73 Jun. 9 at 5:03 AM

$CMPS the charts show this has officially cooled from that run up. If we see slow growth over the next two weeks I think we can get back up to $14 and hold. The chart is not primed for a crazy run but a slow one maybe

0 · Reply

Kfleischmann Jun. 9 at 2:14 AM

$CMPS well ill look at it this way, a few minths ago i would if been smiling my face off to see $10, so will stay long and strong with my shares and average. only a matter of time until this gets what it deserves and cruises up to $20, should at least be with $DFTX and will be curious to see their data, sure it will be good. durability results for $CMPS on deck.

0 · Reply

thevert123 Jun. 8 at 10:48 PM

$CMPS 4hr chart. What do you see? Do you see a stock breaking down or do you see a stock riding the 100ma correcting after a 3.50 to 14.76 move. I'm still bullish and i think tomorrow is going to tell the tale. Do we break down under the 100ma or do we start gaining back some momentum. Its primed and ready for another big run. I think we see slow creep until early q3 results, but who knows? Sometimes all it takes is a strong green day to attract buyers and bring back the momentum. Bullish long term. Neutral short term

2 · Reply

Millionaire11 Jun. 8 at 8:05 PM

$CMPS let me guess you shorted right at open and closed and $11.61

1 · Reply

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 1, 2026, 10:00 AM EDT - 7 days ago

Why Trump Is Pushing Psychedelics To Treat Mental Illness

May 31, 2026, 8:00 AM EDT - 8 days ago

Why Trump reversed course to fast-track psychedelic drugs for mental healthcare

May 28, 2026, 6:30 AM EDT - 11 days ago

Compass Pathways Elects Kathleen Tregoning to Board of Directors

May 26, 2026, 6:30 AM EDT - 13 days ago

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026

May 19, 2026, 10:00 AM EDT - 20 days ago

COMPASS Pathways Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-15T15:28:25.000Z - 24 days ago

Compass Pathways price target raised to $20 from $12 at Maxim

2026-05-14T18:50:44.000Z - 25 days ago

Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

ATAI CMND DFTX ENVB GHRS MIRA NRXP

2026-05-14T16:52:26.000Z - 25 days ago

Compass Pathways price target raised to $17 from $16 at Morgan Stanley

May 14, 2026, 6:30 AM EDT - 25 days ago

Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026

May 13, 2026, 8:00 AM EDT - 26 days ago

COMPASS Pathways Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 26 days ago

COMPASS Pathways Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 26 days ago

COMPASS Pathways Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 26 days ago

COMPASS Pathways Earnings release: Q1 2026

2026-05-13T11:23:45.000Z - 26 days ago

Compass Pathways reports Q1 EPS (30c), consensus (31c)

2026-05-13T11:19:03.000Z - 26 days ago

Compass Pathways expects cash position to fund the company into 2028

May 13, 2026, 7:00 AM EDT - 26 days ago

COMPASS Pathways Slides: Investor presentation

May 13, 2026, 6:30 AM EDT - 26 days ago

Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights

2026-05-07T18:24:07.000Z - 4 weeks ago

Psychedelic: Jefferies initiates Compass Pathways with a Buy rating

CMND ENVB JNJ NRXP SILO

May 6, 2026, 6:30 AM EDT - 4 weeks ago

Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

2026-05-03T23:55:09.000Z - 5 weeks ago

Compass Pathways initiated with a Buy at Jefferies

JNJ

2026-04-30T18:56:54.000Z - 5 weeks ago

Psychedelic: FDA awards Compass Pathways priority review voucher

CMND HELP SILO

Apr 27, 2026, 11:00 AM EDT - 6 weeks ago

COMPASS Pathways Transcript: Needham Virtual Psychedelics Forum

2026-04-24T17:41:05.000Z - 6 weeks ago

Oppenheimer says CNPV designation strengthens case for Compass Pathways’ COMP360

2026-04-24T14:45:52.000Z - 6 weeks ago

Compass Pathways announces FDA granted NDA rolling review request

Apr 24, 2026, 10:37 AM EDT - 6 weeks ago

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

2026-04-24T12:57:10.000Z - 6 weeks ago

Compass Pathways initiated with a Buy at B. Riley

2026-04-21T10:54:16.000Z - 6 weeks ago

Compass Pathways enters collaboration with Osmind

Apr 21, 2026, 6:30 AM EDT - 6 weeks ago

Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments

Apr 20, 2026, 2:05 PM EDT - 7 weeks ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI DFTX HELP GHRS

Apr 20, 2026, 10:45 AM EDT - 7 weeks ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

ATAI DFTX GHRS

Apr 20, 2026, 8:26 AM EDT - 7 weeks ago

Psychedelic stocks rally with Trump's support

ATAI DFTX GHRS

Apr 20, 2026, 8:18 AM EDT - 7 weeks ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

ATAI GHRS DFTX

Apr 20, 2026, 6:43 AM EDT - 7 weeks ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI DFTX ENVB GHRS HELP

Apr 20, 2026, 6:30 AM EDT - 7 weeks ago

Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026

2026-04-19T17:05:44.000Z - 7 weeks ago

Compass Pathways ‘commends’ White House Executive Order to accelerate research

Apr 18, 2026, 4:12 PM EDT - 7 weeks ago

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Apr 15, 2026, 8:00 AM EDT - 7 weeks ago

COMPASS Pathways Proxy statement: Proxy filing

Apr 14, 2026, 12:45 PM EDT - 7 weeks ago

COMPASS Pathways Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 6:30 AM EDT - 7 weeks ago

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Apr 8, 2026, 6:30 AM EDT - 2 months ago

Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026

Mar 24, 2026, 7:30 AM EDT - 2 months ago

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Mar 24, 2026, 7:00 AM EDT - 2 months ago

COMPASS Pathways Annual report: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 2 months ago

COMPASS Pathways Earnings release: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 2 months ago

COMPASS Pathways Annual report: Q4 2025

Mar 18, 2026, 10:30 AM EDT - 2 months ago

COMPASS Pathways Transcript: Stifel 2026 Virtual CNS Forum

Mar 12, 2026, 6:30 AM EDT - 3 months ago

Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026

Mar 3, 2026, 10:30 AM EST - 3 months ago

COMPASS Pathways Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 6:30 AM EST - 3 months ago

Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants

Feb 24, 2026, 6:39 AM EST - 3 months ago

Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026

Feb 18, 2026, 8:18 PM EST - 3 months ago

Compass Pathways Announces Pricing of $150 Million Public Offering

Feb 17, 2026, 4:06 PM EST - 3 months ago

Compass Pathways Launches Proposed $150.0 Million Public Offering

Feb 17, 2026, 8:00 AM EST - 3 months ago

COMPASS Pathways Transcript: Study update

Feb 17, 2026, 8:00 AM EST - 3 months ago

COMPASS Pathways Press release: Study update

Feb 17, 2026, 8:00 AM EST - 3 months ago

COMPASS Pathways Slides: Study update

Feb 17, 2026, 6:42 AM EST - 3 months ago

Compass Pathways' depression treatment meets main goal in late‑stage study

Feb 17, 2026, 6:30 AM EST - 3 months ago

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Feb 16, 2026, 8:00 AM EST - 4 months ago

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Feb 9, 2026, 5:01 PM EST - 4 months ago

COMPASS Pathways Plc ADR (CMPS) Price Forecast: Bullish Reversal Gains Structure

Jan 7, 2026, 10:00 AM EST - 5 months ago

COMPASS Pathways Transcript: KOL Event

Jan 7, 2026, 10:00 AM EST - 5 months ago

COMPASS Pathways Press release: KOL Event

Jan 7, 2026, 10:00 AM EST - 5 months ago

COMPASS Pathways Slides: KOL Event

Jan 7, 2026, 7:00 AM EST - 5 months ago

COMPASS Pathways Slides: Investor Presentation

Jan 7, 2026, 6:30 AM EST - 5 months ago

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Jan 6, 2026, 6:30 AM EST - 5 months ago

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

Dec 9, 2025, 6:30 AM EST - 6 months ago

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Dec 3, 2025, 1:30 PM EST - 6 months ago

COMPASS Pathways Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 10:00 AM EST - 6 months ago

COMPASS Pathways Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 20, 2025, 6:30 AM EST - 7 months ago

Compass Pathways to Participate in Two Investor Conferences in December

Nov 11, 2025, 10:40 AM EST - 7 months ago

COMPASS Pathways Transcript: Stifel 2025 Healthcare Conference

Nov 5, 2025, 6:30 AM EST - 7 months ago

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

Nov 4, 2025, 9:30 AM EST - 7 months ago

COMPASS Pathways Slides: Investor Presentation

Nov 4, 2025, 8:00 AM EST - 7 months ago

COMPASS Pathways Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

COMPASS Pathways Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

COMPASS Pathways Earnings release: Q3 2025

Nov 4, 2025, 6:45 AM EST - 7 months ago

Compass Pathways to expedite launch timing of its experimental depression therapy

Nov 4, 2025, 6:30 AM EST - 7 months ago

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

Oct 30, 2025, 8:30 AM EDT - 7 months ago

NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression

Oct 29, 2025, 6:30 AM EDT - 7 months ago

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

Oct 28, 2025, 6:30 AM EDT - 7 months ago

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

Sep 2, 2025, 6:30 AM EDT - 9 months ago

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

Aug 27, 2025, 6:30 AM EDT - 10 months ago

Compass Pathways to Participate in Four Investor Conferences in September

Aug 12, 2025, 4:00 PM EDT - 10 months ago

COMPASS Pathways Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 5, 2025, 6:30 AM EDT - 10 months ago

Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

Jul 31, 2025, 8:00 AM EDT - 11 months ago

COMPASS Pathways Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 11 months ago

COMPASS Pathways Earnings release: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 11 months ago

COMPASS Pathways Quarterly report: Q2 2025

Jul 31, 2025, 6:30 AM EDT - 11 months ago

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

Jul 29, 2025, 6:30 AM EDT - 11 months ago

Compass Pathways Appoints Justin Gover to Board of Directors

Jul 22, 2025, 6:30 AM EDT - 11 months ago

Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

Jul 10, 2025, 4:00 PM EDT - 11 months ago

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

Jun 23, 2025, 8:12 AM EDT - 1 year ago

Compass Pathways stock slip as psilocybin depression trial falls short of expectations

Jun 23, 2025, 6:48 AM EDT - 1 year ago

Compass Pathways' depression drug succeeds late-stage trial

Jun 23, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

May 20, 2025, 10:30 AM EDT - 1 year ago

COMPASS Pathways Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 14, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Indialli1309 Jun. 9 at 8:29 AM

$CMPS There is something good cooking! Last time CMPS was on the top 10 in TRENDING it went 40% up!

1 · Reply

Indialli1309 Jun. 9 at 8:09 AM

$CMPS Let’s stop sucking our thumb! CMPS is a fantastic company with a fantastic product. Two options, buy or hold. This is happening😇

0 · Reply

Indialli1309 Jun. 9 at 8:07 AM

$CMPS https://vicentellp.com/insights/comp360-rems-and-what-fda-psychedelic-approval-path-means-for-investors-and-operators/

0 · Reply

Indialli1309 Jun. 9 at 8:04 AM

$CMPS https://www.medicaldaily.com/chicagos-va-hospital-just-enrolled-its-first-veterans-psilocybin-assisted-therapy-program-475537

0 · Reply

Sibtsen Jun. 9 at 5:45 AM

0 · Reply

Hobson73 Jun. 9 at 5:05 AM

$CMPS anyone here have an average in the $2 range? Show receipts so I can be jealous

0 · Reply

Hobson73 Jun. 9 at 5:03 AM

0 · Reply

Kfleischmann Jun. 9 at 2:14 AM

0 · Reply

thevert123 Jun. 8 at 10:48 PM

2 · Reply

Millionaire11 Jun. 8 at 8:05 PM

$CMPS let me guess you shorted right at open and closed and $11.61

1 · Reply

TurdSniper Jun. 8 at 8:00 PM

$CMPS Millionaire11 was wrong again! 🤣⬇

0 · Reply

Millionaire11 Jun. 8 at 4:33 PM

$CMPS I think there is a big possibility Donald Trump might mention this stock by name once FDA approved. And we know what happens when he mentions a stock

2 · Reply